{"id":1039,"date":"2018-02-16T08:53:39","date_gmt":"2018-02-16T13:53:39","guid":{"rendered":"https:\/\/www.stockcalc.com\/blog\/Reports\/?p=1039"},"modified":"2018-02-16T08:53:39","modified_gmt":"2018-02-16T13:53:39","slug":"agios-pharmaceuticals-agionas-fundamental-valuation-report","status":"publish","type":"post","link":"https:\/\/www.stockcalc.com\/blog\/Reports\/2018\/02\/16\/agios-pharmaceuticals-agionas-fundamental-valuation-report\/","title":{"rendered":"Agios Pharmaceuticals (AGIO:NAS) Fundamental Valuation Report"},"content":{"rendered":"
\n
\n
\n

\n <\/path>\n <\/path>\n <\/path>\n <\/path>\n <\/svg>
\n Print<\/a>\n <\/div>\n

\n
\n
\n This Report was generated using the tools available on StockCalc.com<\/a>. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer<\/a>.
\n To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc here<\/a>.
\n <\/em>\n <\/div>\n

Valuation Summary:<\/h3>\n

Agios Pharmaceuticals<\/strong><\/span> $77.97 (USD) Close Price as of 14\/02\/2018<\/span><\/p>\n

\n Based on the analysis conducted in this report, Agios Pharmaceuticals<\/strong>, (AGIO:NAS) is found to be  Undervalued<\/span>.\n <\/p>\n<\/p><\/div>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Company<\/td>\nAgios Pharmaceuticals<\/td>\n<\/tr>\n
Symbol:Exchange<\/td>\nAGIO:NAS<\/td>\n<\/tr>\n
Industry<\/td>\nHealthcare:Biotechnology<\/td>\n<\/tr>\n
Close Price\/Date<\/td>\n$77.97 (USD) 14\/02\/2018<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/tr>\n
Weighted Average Valuation<\/td>\n$82.66 (USD)<\/strong><\/td>\n<\/tr>\n
Summary<\/td>\nAGIO:NAS is found to be  Undervalued<\/span> by 6.0% using the 3 valuation models shown below.<\/td>\n<\/tr>\n
Valuation Models Used<\/td>\nAnalyst Consensus: $84.33 (USD)<\/td>\n<\/tr>\n
(in order of importance)<\/td>\nComparables: $92.06 (USD)<\/td>\n<\/tr>\n
<\/td>\nAdjusted Book Value: $58.87 (USD)<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/tr>\n
Valuation Methods Analysis<\/td>\nThis company is:<\/td>\n<\/tr>\n
Cash Flow Basis:<\/td>\nOvervalued<\/span> on a Cash Flow Valuation basis<\/td>\n<\/tr>\n
Comparable Company Basis:<\/td>\nUndervalued<\/span> on a Comparable Valuation basis<\/td>\n<\/tr>\n
Asset Basis:<\/td>\nOvervalued<\/span> on an Asset Valuation basis<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n <\/p>\n
\n

Valuation Details<\/h3>\n<\/p><\/div>\n
\n

\n Agios Pharmaceuticals Valuations
\n <\/h4>\n
\"Summary<\/div>\n

 We have up to 6 valuation points for each company. Details are at the bottom of the report.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n

\n
\n

Discounted Cash Flow and Sensitivity Analysis for AGIO:NAS<\/h3>\n<\/p><\/div>\n

\n Using a discounted cash flow model generates a negative intrinsic value due to one of 1) zero or negative projected cash flows 2) excessive capital expenditures or 3) excessive debt to calculated equity value for AGIO:NAS<\/strong>. We have not shown the calculated value here for that reason.<\/p>\n

Sensitivity Analysis<\/h4>\n

(showing how changes in the input variables impact the DCF calculation)<\/span><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
AGIO:NAS<\/th>\nCurrent Values<\/th>\nValuation If Dropped *<\/th>\nValuation If Raised *<\/th>\n<\/tr>\n
Calculated Value:<\/th>\n<\/th>\n1%<\/th>\n5%<\/th>\n1%<\/th>\n5%<\/th>\n<\/tr>\n<\/thead>\n
WACC (or Ke)<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Terminal Growth Rate<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Tax Rate<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Cash Flow<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Capital Expenditures<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Long Term Debt<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

* Changes are absolute: ex WACC from 8% to 7%<\/p>\n<\/p><\/div>\n

\n
\n

Comparables Model<\/h3>\n<\/p><\/div>\n

Using similar companies and price based ratios we generated a valuation of $76.92 (USD)<\/strong> for AGIO:NAS<\/strong>. We also generated a valuation of $92.06 (USD)<\/strong> using other metrics and comparables.
\n The comparable companies were ACADIA Pharmaceuticals (ACAD:NAS), Array BioPharma (ARRY:NAS), Amicus Therapeutics (FOLD:NAS), Intercept Pharmaceuticals (ICPT:NAS) and Madrigal Pharmaceuticals (MDGL:NAS)\n <\/p>\n

\n\n\n\n\n\n\n\n
Company AGIO:NAS<\/th>\nEnd Date Value<\/th>\n<\/tr>\n
Cash\/Share<\/td>\n$0.00 (USD)<\/span><\/td>\n<\/tr>\n
Book Value\/Share<\/td>\n$8.07 (USD)<\/span><\/td>\n<\/tr>\n
MarketCap<\/td>\n4,343,517,049<\/span><\/td>\n<\/tr>\n
1 Year Return<\/td>\n0.681<\/span><\/td>\n<\/tr>\n
NetPPE<\/td>\n0<\/span><\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n
Price Based on Comps<\/th>\nAdjustment Factor (%)<\/th>\n<\/tr>\n
$0.00 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
$109.15 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
$43.19 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
$123.83 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
$0.00 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n
Ratios Used<\/th>\nAverage Values<\/th>\nACAD:NAS<\/th>\nARRY:NAS<\/th>\nFOLD:NAS<\/th>\nICPT:NAS<\/th>\nMDGL:NAS<\/th>\n<\/tr>\n
Cash \/ Share<\/td>\n0.15<\/span><\/td>\n0.00<\/td>\n0.73<\/td>\n0.00<\/td>\n0.00<\/td>\n0.00<\/td>\n<\/tr>\n
Book Value \/ Share<\/td>\n3.69<\/span><\/td>\n3.61<\/td>\n0.46<\/td>\n2.16<\/td>\n8.40<\/td>\n3.81<\/td>\n<\/tr>\n
Market Cap<\/td>\n2,092,861,510<\/span><\/td>\n3,903,208,264<\/td>\n1,868,508,830<\/td>\n1,835,995,078<\/td>\n2,367,632,080<\/td>\n488,963,296<\/td>\n<\/tr>\n
1 Year Return<\/td>\n1.67<\/span><\/td>\n-0.22<\/td>\n0.44<\/td>\n1.58<\/td>\n-0.58<\/td>\n7.13<\/td>\n<\/tr>\n
Net PPE<\/td>\n8,132,000<\/span><\/td>\n0<\/td>\n8,132,000<\/td>\n0<\/td>\n0<\/td>\n0<\/td>\n<\/tr>\n<\/table><\/div>\n<\/p><\/div>\n
\n
\n

Multiples<\/h3>\n<\/p><\/div>\n

Using a multiples approach we generated a valuation of  $52.33 (USD)<\/strong> for AGIO:NAS<\/strong><\/p>\n

\n\n\n\n\n\n\n\n
Company AGIO:NAS<\/th>\nEnd Date Value<\/th>\n<\/tr>\n
Earnings\/Share<\/td>\n($6.29) (USD)<\/span><\/td>\n<\/tr>\n
Book Value\/Share<\/td>\n$8.07 (USD)<\/span><\/td>\n<\/tr>\n
Sales\/Share<\/td>\n$1.24 (USD)<\/span><\/td>\n<\/tr>\n
Cash Flow\/Share<\/td>\n($5.83) (USD)<\/span><\/td>\n<\/tr>\n
EBITDA\/Share<\/td>\n($4.35) (USD)<\/span><\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n
Price Based on Comps<\/th>\nAdjustment Factor<\/th>\n<\/tr>\n
$0.00 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
$55.97 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
$48.70 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
$0.00 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
$0.00 (USD)<\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n
Ratios<\/th>\nRatio Average<\/th>\n<\/tr>\n
PE Ratio<\/td>\n35.86<\/span><\/td>\n<\/tr>\n
PB Ratio<\/td>\n6.93<\/span><\/td>\n<\/tr>\n
PS Ratio<\/td>\n39.16<\/span><\/td>\n<\/tr>\n
PCF Ratio<\/td>\n28.62<\/span><\/td>\n<\/tr>\n
EV to EBITDA<\/td>\n0.00<\/span><\/td>\n<\/tr>\n<\/table><\/div>\n<\/p><\/div>\n
\n
\n

Adjusted Book Value versus Historical Price to Book<\/h3>\n<\/p><\/div>\n

The average the Price to Book ratio for  AGIO:NAS<\/strong> for the last 5 years was  6.93<\/strong>
\n
We ran the Adjusted Book Value for  AGIO:NAS<\/strong> and generated a book value of  $8.49 (USD)<\/strong>
\n By multiplying these we get an adjusted valuation of  $58.87 (USD)<\/strong><\/p><\/div>\n

\n
\n

Analyst Data<\/h3>\n<\/p><\/div>\n
\n
\n In the Stockcalc database there are 3 analysts that provide a valuation for AGIO:NAS<\/strong>. The 3 analysts have a concensus valuation for AGIO:NAS<\/strong> for 2018 of $84.33 (USD)<\/strong>.<\/p>\n

AGIO:NAS Agios Pharmaceuticals<\/h4>\n\n\n\n
Analyst Recommendation<\/td>\n<\/tr>\nBuy<\/td>\nHold<\/td>\nSell<\/td>\nRating
(of 5)<\/td>\n		Guidance<\/td>\nAs Of<\/td>\n<\/tr>\n
3<\/td>\n0<\/td>\n0<\/td>\n5.0000<\/td>\nBuy<\/td>\n2018-2-13<\/td>\n<\/tr>\n<\/table>\n

Current Price: not available<\/p>\n<\/div>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Analyst Consensus<\/td>\n<\/tr>\n
USD Millions<\/td>\n2017<\/td>\n2018<\/td>\n2019<\/td>\n<\/tr>\n
Mean EPS<\/td>\n-6.78<\/td>\n-7.52<\/td>\n-0.23<\/td>\n<\/tr>\n
# EPS Analysts<\/td>\n2<\/td>\n2<\/td>\n2<\/td>\n<\/tr>\n
Mean Revenue<\/td>\n50.70<\/td>\n138.90<\/td>\n558.10<\/td>\n<\/tr>\n
# Revenue Analysts<\/td>\n2<\/td>\n2<\/td>\n2<\/td>\n<\/tr>\n
Mean Target Price<\/td>\n<\/td>\n84.33<\/td>\n<\/td>\n<\/tr>\n
Mean Cash Flow<\/td>\n-5.43<\/td>\n-6.03<\/td>\n-0.32<\/td>\n<\/tr>\n
Mean EBITDA<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Mean Net Income<\/td>\n-306.90<\/td>\n-356.80<\/td>\n-11.80<\/td>\n<\/tr>\n
Mean Debt Outstanding<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Mean Tax Rate<\/td>\n0.00<\/td>\n0.00<\/td>\n0.00<\/td>\n<\/tr>\n
Mean Growth Rate<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Mean Capital Expenditure<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/table><\/div>\n
<\/div>\n<\/p><\/div>\n<\/p><\/div>\n
\n
\n
\n

Company Overview (AGIO:NAS USD)<\/h3>\n<\/p><\/div>\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n\n
Price<\/td>\n77.97<\/td>\n<\/tr>\n
Range<\/td>\n74.99 – 78.50<\/td>\n<\/tr>\n
52 week<\/td>\n46.67 – 80.72<\/td>\n<\/tr>\n
Open<\/td>\n76.06<\/td>\n<\/tr>\n
Vol \/ Avg.<\/td>\n1.02M\/574876<\/td>\n<\/tr>\n
Mkt cap<\/td>\n3.79B<\/td>\n<\/tr>\n
P\/E<\/td>\n0.00<\/td>\n<\/tr>\n
Div\/yield<\/td>\n0.00\/0.00<\/td>\n<\/tr>\n
EPS<\/td>\n-5.07<\/td>\n<\/tr>\n
Shares<\/td>\n48.62M<\/td>\n<\/tr>\n
Beta<\/td>\n0.94<\/td>\n<\/tr>\n<\/table>\n<\/div>\n
\"Summary\n <\/div>\n
<\/div>\n<\/p><\/div>\n<\/p><\/div>\n
\n
\n

Detailed Company Description<\/h3>\n<\/p><\/div>\n

Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n

\n
\n

Explanation of Valuation Models<\/h3>\n<\/p><\/div>\n
\n
\n We have up to 6 valuation points for each company in the database.
\n The Discounted Cash Flow (DCF)<\/span> valuation is a cash flow model where cash flow projections are discounted back to the present to calculate value per share. DCF is a common valuation technique especially for companies undergoing irregular cash flows such as resource companies (mining, forestry, oil and gas) going though price cycles or smaller companies about to generate cash flow (junior exploration companies, junior pharma, technology firms…).
\n The Price Comparables<\/span> valuation is the result of valuing the company we are looking at on the basis of ratios from selected comparable companies: Price to Earnings, Price to Book, Price to Sales, Price to Cash Flow, Enterprise Value (EV) to EBITDA. Each of these ratios for the selected comparable companies are averaged and multiplied by the values for the company we are interested in to calculate a value per share for our selected company.
\n We have included the Other Comparables<\/span> as a way to value companies that cannot be valued using Earnings based ratios. This technique is very useful for companies still experiencing negative cash flows such as mining exploration firms. We use Cash\/Share, Book Value\/Share, MarketCap, 1 Year Return, NetPPE as the ratios here. Each of these ratios for the selected comparable companies are averaged and multiplied by the values for the company we are interested in to calculate a value per share for our selected company.
\n Multiples<\/span> are similar to Price comparables where we look at current or historic ratios for the company in question to assess what it should be worth today based on those historic ratios. We use the same 5 ratios as in the price comparables and value the company with its historic averages.
\n With Adjusted Book Value (ABV)<\/span> we calculate the book value per share for the company based on its balance sheet and multiply that book value per share by its historical price to book ratio to calculate a value per share.
\n If we have Analyst coverage<\/span> for the company we use the consensus target price here.\n <\/div>\n<\/p><\/div>\n
\n

Notice to User<\/h3>\n<\/p><\/div>\n

\n
\n The contents of this report and the Stockcalc website are provided on an ‘‘as is<\/strong>’’ or ‘‘as available<\/strong>’’ basis with all faults and may not be current in all cases. The information in this report or on the website is subject to continuous change and Patchell Brook Equity Analytics Inc. assumes no responsibility to update or amend such information or that the information will be current. Patchell Brook Equity Analytics Inc. does not claim that all information, calculations or opinions presented in this report or on its website are true, reliable, or complete. Accordingly, you should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment or other decision. Any information, data, opinions, calculations or recommendations provided by third parties through links to other websites or otherwise made available through this report or website are solely those of the third party and not of Patchell Brook Equity Analytics Inc. Please refer to the Terms of Use on www.stockcalc.com<\/a> for further information.
\n To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc here<\/a>.
\n <\/em>\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n

\n
\n <\/circle><\/path><\/path><\/svg><\/p>\n
\n Please read this notice carefully: By accessing this website, you acknowledge and agree to the following:<\/strong>
\n Show text.<\/a><\/p>\n
\n <\/a>
\n Patchell Brook Equity Analytics Inc. Website Disclaimer:<\/strong>
\n (for any or all of www.patchellbrook.com, www.stockcalc.com or www.eqyst.com which may be referred to as “website”, “the website” , “this website”, “its website” or ” Patchell Brook Equity Analytics Inc. website” in this website disclaimer)<\/strong>
\n Entering this website constitutes a legal and valid electronic signature and hence, represents evidence of your express consent to be bound by the terms and conditions of this legal disclaimer. If you disagree with any part of this disclaimer, or are unclear as to the meaning of any part of this legal disclaimer, entering this website is strictly prohibited. By agreeing to enter this website, both authorized and unauthorized users waive their right to later pursue any form of legal action in any jurisdiction for any loss, harm, or damage, however caused, resulting from accessing this website<\/p>\n

Investment Decisions:<\/h4>\n

Persons accessing this website are strongly encouraged to obtain appropriate professional advice before making any investment or financial decision as the website and all of its contents may not be considered as grounds for an investment or other decision.<\/p>\n

As Is:<\/h4>\n

The contents of this website are provided on an “as is” or “as available” basis with all faults and may not be current in all cases. The information on this website is subject to continuous change, and Patchell Brook Equity Analytics Inc. assumes no responsibility to update or amend such information. Patchell Brook Equity Analytics Inc. does not claim that all information or opinions presented on its website are true, reliable, or complete. Accordingly, you should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment or other decision. Any information, data, opinions or recommendations provided by third parties through links to other websites or otherwise made available through this website are solely those of the third party and not of Patchell Brook Equity Analytics Inc.
\n Patchell Brook Equity Analytics Inc. makes all reasonable efforts to ensure it receives information from sources it deems reliable, fair, and accurate. Information provided by Patchell Brook Equity Analytics Inc. and information provided by those other sources on this website is not subject to any guarantee as to its accuracy or completeness or as to its currency. Neither Patchell Brook Equity Analytics Inc. nor any third party owner, licensor or supplier of information used or made available through this website, including market data, quotation information and databases, and including news, articles, text, graphs, audio clips, video clips, broadcasts and seminars (“Data”) makes or is liable for any representation, warranty or condition, whether express or implied, concerning the Data or the use thereof including, without limitation, that (i) the Data will meet your needs, or that the Data will be available for use at any particular time or for any particular purpose or will be error free, or (ii) the Data is up-to-date, accurate, in sequence, reliable, complete or suitable for any purpose. Further, Patchell Brook Equity Analytics Inc. disclaims any implied warranty of merchantability or non-infringement.
\n Database Information provided by Morningstar is copyrighted © 2016 Morningstar. All Rights Reserved. The database or other information where identified contained herein: (1) is proprietary to Morningstar and\/or it content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or loss arising from any use of this information. Past performance is no guarantee of future results.
\n Changes may be made at any time to this service and the information contained therein without prior notice.<\/p>\n

Rules of Use:<\/h4>\n

Patchell Brook Equity Analytics Inc. may, from time to time, change the rules that govern your use of this website. Patchell Brook Equity Analytics Inc. shall have the right at any time, without providing individual notice, to change, modify, add, or delete the terms and conditions applicable to your use of the website or any part thereof. Any changed terms shall be effective immediately upon notice thereof, which may be given by any means including, but not limited to, posting the changed terms on the website, by electronic or conventional mail, or by any other means by which you obtain notice thereof. Any use of the website by you after such notice shall be deemed to constitute acceptance by you of the changed terms.<\/p>\n

Service Interruptions:<\/h4>\n

Patchell Brook Equity Analytics Inc. endeavours to offer customers an electronic service that is easy to use, reliable, secure and capable of meeting their investment information needs. From time to time, however, interruptions, errors or other deficiencies in service may occur. This may be due to a variety of factors, some of which are outside the control of Patchell Brook Equity Analytics Inc., including interruptions in the accessibility of the Internet, a system outage in facilities of a third party service provider (including stock exchanges, Data providers and back office service providers), and market conditions that may result in general market volatility, volatility affecting a particular security or class of securities, or heavy demand and high volumes of trading activity.
\n By entering, you expressly accept that Patchell Brook Equity Analytics Inc. does not warrant, guarantee, or represent (expressly or impliedly) that the website is free from technical malfunction or human error, or that any services obtained through this website are of fitting quality and suitable for any particular purpose, and you expressly accept that Patchell Brook Equity Analytics Inc. will not and cannot be held liable (in all forms of legal liability) for any errors, inaccuracies or omissions (including any third party) and any loss or damages, whether incidental, consequential, or otherwise, resulting from its use or inability to use by any party, or in connection with any error, interruption, delay in operation or incomplete transmission, or line or system failure
\n Without limiting the foregoing, “real time” or “delayed” quotes viewed on this website, particularly in times of high volumes of trading and market volatility, may not be reflective of a current trading price of a security. Further, all express or implied, direct or indirect, representations, warranties and conditions in respect of Data arising or implied by statute, common law, custom, usage of trade, course of performance, course of dealing or otherwise, including but not limited to any warranties or conditions of merchantable quality and fitness for a particular purpose are expressly excluded.<\/p>\n

Own Risk:<\/h4>\n

Patchell Brook Equity Analytics Inc. emphasizes that all activities conducted by users at or via this website are at their own risk. The user assumes all risks associated with the use of this website including, but not limited to, all terms and conditions mentioned in this legal disclaimer. The content, accuracy, opinions expressed, and other internal or external links provided at these sites are not investigated, verified, modified, or endorsed by Patchell Brook Equity Analytics Inc. Users are solely responsible for making all enquiries and investigation before proceeding with any online or offline access or transaction with any of these third parties. <\/p>\n

Other users located on the Patchell Brook Equity Analytics Inc. website may express their opinions or present their analysis for consumption in various locations available on the Patchell Brook Equity Analytics Inc. website. All users assume their own risk associated with any information they obtain from other users located on the Patchell Brook Equity Analytics Inc. website. Patchell Brook Equity Analytics Inc. disclaims all liabilities regarding the content of these pages and any use thereof that could be made by any person. Patchell Brook Equity Analytics Inc. expressly disclaims any liability for losses or damages, whether direct, indirect, specific or consequential incurred by any user of this website and whether by contract, negligence or otherwise.<\/p>\n

Personal Use:<\/h4>\n

The information and opinions included on this website are made available by Patchell Brook Equity Analytics Inc. for informational and personal use only and they may be modified without prior notice.
\n You may view, print, or store temporarily extracts from this website without alteration, addition, or deletion for the purposes only of your own reference and personal, non-commercial use. If you legitimately download information or software from this website, where it is available to be legitimately downloaded, you agree that you will not copy, remove, or obscure any copyright or other notices or legends contained in any such information. Except as otherwise provided in this paragraph; neither this website nor any part of it may be otherwise copied, reproduced, distributed, or transmitted in any media (including, without limitation, via any other website) without the written permission of Patchell Brook Equity Analytics Inc. No other use of the information or materials contained on this website is permitted. All rights reserved. Patchell Brook Equity Analytics Inc. reserves the right to pursue any necessary legal action for any copyright infringement
\n Data analysis and\/or reports produced for consumption or sale though the Patchell Brook Equity Analytics Inc. storefront are an accepted use of the data and tools and are contained within the Patchell Brook Equity Analytics Inc. website. These reports and analysis are only to be made available on the Patchell Brook Equity Analytics Inc. website. Any reproduction for use of these reports and analysis beyond the Patchell Brook Equity Analytics Inc. website is strictly prohibited.
\n Patchell Brook Equity Analytics Inc. also strictly prohibits the use of technologies such as “Screen Scraping” or other similar or related technologies used for the capture of data from the Patchell Brook Equity Analytics Inc. website. All data is to be maintained on the Patchell Brook Equity Analytics Inc. website unless otherwise specifically identified. Data, reports and all other information are not to be downloaded to any other device, hard drive or similar technology unless expressly identified on the Patchell Brook Equity Analytics Inc. website.<\/p>\n

Access Levels:<\/h4>\n

Access to the Patchell Brook Equity Analytics Inc. website is enabled to allow clients to access their analysis, portfolios and related information. Access levels, which can vary from customer to customer, depend upon the level of access granted via the subscription model.
\n This website is designed to be accessed through its principal home page and such other pages as we may decide. If you access the site through individual pages directly, which are not designed for this purpose, you may not see important information which is relevant to a full understanding of our products and services. In addition to this important Information, you will be referred on certain site pages to read or view help, tutorials or instructional video or other related instructional material. These may contain important product details and relevant legal or regulatory information and must be read or viewed together with the relevant site pages.<\/p>\n

Instructional material:<\/h4>\n

Case examples, video instruction, tutorials, help menus, sample calculations, definitions and all other related information (“the instructional material”) are for illustrative purposes only. They are not intended to reflect, nor should they be interpreted, as an indication of future values or returns on investment and are not guaranteed to be accurate or complete. Video instruction is solely made available to assist the user in navigation and understanding of the website. Patchell Brook Equity Analytics Inc. nor the other providers of data on this website make any representations or warranties, express or implied, as to the accuracy, completeness, or fitness for any purpose or use of the instructional material provided. The instructional materials are not intended to be, or construed as, financial, tax or investment advice<\/p>\n

No Tax, Law, Solicitation:<\/h4>\n

No information appearing on this website shall be deemed as an offer of services or products from Patchell Brook Equity Analytics Inc. or as a recommendation or offer to purchase or sell or as the solicitation of an offer to purchase or sell securities, futures, options, or any other investment product or to provide any investment advice or service. This website is not intended to provide legal, accounting, tax advice or any other advice and should not be relied upon in that regard.<\/p>\n

No Liability:<\/h4>\n

Patchell Brook Equity Analytics Inc. accepts no liability whatsoever for any loss or damage, or otherwise as stipulated in this legal disclaimer, arising from the use of any section of this website, whether or not such loss or damage is caused by reason of negligence, or otherwise on the part of Patchell Brook Equity Analytics Inc.<\/p>\n

Indemnity:<\/h4>\n

You agree to defend, indemnify, and hold Patchell Brook Equity Analytics Inc., its subsidiaries, affiliates, successors, assigns, and their respective shareholders, directors, officers, employees, and agents harmless from and against any and all claims, damages, costs, and expenses, including attorneys’ fees, arising from or related to your use of the website.<\/p>\n

Jurisdiction:<\/h4>\n

Information contained herein is not intended to be published or made available to any person in any jurisdiction where doing so would result in contravention of any applicable laws or regulations. Access to the products and services described herein may be subject to restrictions vis-à-vis certain persons or in certain countries. None of the products or services presented herein shall be supplied by Patchell Brook Equity Analytics Inc. to a person in the event that the law of his\/her country of origin, or any other country concerning him\/her, prohibits it. The reader of this message should ensure that he\/she is legally authorized to access this website in the country or territory from where the access is gained. Accordingly, if it is prohibited to make such information available in your jurisdiction or to you (by reason of your nationality, residence, or otherwise), this information is not directed at you. Before reviewing the pages of this website, you must be satisfied that doing so will not result in such a contravention and is not prohibited.
\n These terms and conditions shall be governed and construed in accordance with the laws of the Province of New Brunswick, Canada without giving effect to the conflict of laws principles thereof. The courts of the Province of New Brunswick, Canada, shall have exclusive jurisdiction in respect to any dispute that may arise hereunder.<\/p>\n

Links:<\/h4>\n

Patchell Brook Equity Analytics Inc. has no control or liability regarding any links or the creation of any links to other sites external to Patchell Brook Equity Analytics Inc. and regarding the content of said sites. Therefore, you accept that your choice to access another site through a hypertext link is made under your own responsibility, and Patchell Brook Equity Analytics Inc. shall not be liable for any damages that result, directly or indirectly, from your access to another site connected by a hypertext link. Because the materials made available on these sites are not under the control of Patchell Brook Equity Analytics Inc., we make no representation about these sites or the materials that may be included therein. The fact that Patchell Brook Equity Analytics Inc. has linked to these sites does not constitute an endorsement or recommendation of any kind. These links are provided only as a convenience.<\/p>\n

Trademarks and Intellectual Property:<\/h4>\n

Patchell Brook Equity Analytics Inc. and any other names, images, and logos identifying Patchell Brook Equity Analytics Inc. and its products and services are proprietary trademarks of Patchell Brook Equity Analytics Inc.. Patchell Brook Equity Analytics Inc. does not permit the use of its name in advertising, as an endorsement of any product or service, or for any other commercial purpose, except where expressly permitted by written agreement between parties. This website and the copyright in the materials on this website (including all text, information, graphics, animation, and images) is owned by or licensed to Patchell Brook Equity Analytics Inc. All other trademarks, service marks, registered trademarks, or registered service marks mentioned in this website are the property of their respective owners.<\/p>\n

Fees:<\/h4>\n

Patchell Brook Equity Analytics Inc. endeavours to keep the rates and fees posted on this website current. However, rates, fees and related information are subject to change at any time with prior notice to users and the posted rates and fees at this website may not reflect such changes. Some of the services on this website are provided free of charge, but Patchell Brook Equity Analytics Inc. reserves the right to charge for these services in the future.<\/p>\n

Confidentiality:<\/h4>\n

This website is not a secure medium for e-mail or other electronic communications. Any confidential, proprietary or sensitive information transmitted by a user by means of this website through e-mail or other electronic communications may be read and\/or copied by unauthorized persons.<\/p>\n

Security:<\/h4>\n

Users are solely responsible for the actual password(s) chosen by them. Users of this service are solely responsible for maintaining the security of their logon id and password(s), and ensuring that only the user uses the logon id and password(s). User agrees not to disclose their logon id and password(s) to any other person. Patchell Brook Equity Analytics Inc. shall not be responsible for the unauthorized use of the service by any other person with user’s logon id or password(s), and Patchell Brook Equity Analytics Inc. is under no obligation to confirm the actual identity or authority of any user of the logon id or password(s). User shall notify Patchell Brook Equity Analytics Inc. immediately upon becoming aware of any known or suspected unauthorized use of the user’s logon id or password(s) to gain access to the service, or any other breach of security involving user’s logon id or password(s).<\/p>\n

Virus Checks:<\/h4>\n

When using this website, it is up to you to take reasonable precautions to scan for computer viruses and other items of a destructive nature. It is also up to you to ensure that you have a complete and current backup of the information contained on your computer system prior to using this website.<\/p>\n

Right to Suspend:<\/h4>\n

Patchell Brook Equity Analytics Inc. may restrict, suspend or terminate your access to, and use of, all or any part of the Patchell Brook Equity Analytics Inc. website for any reason at any time in Patchell Brook Equity Analytics Inc. absolute discretion and without prior notice or liability
\n YOU ACKNOWLEDGE, BY YOUR USE OF THE WEBSITE, THAT YOUR USE OF THE WEBSITE IS AT YOUR SOLE RISK, THAT YOU ASSUME FULL RESPONSIBILITY FOR ALL COSTS ASSOCIATED WITH YOUR USE OF THE PATCHELL BROOK EQUITY ANALYTICS INC. WEBSITE, AND THAT PATCHELL BROOK EQUITY ANALYTICS INC. SHALL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND RELATED TO YOUR USE OF THIS WEBSITE.<\/strong>
\n PATCHELL BROOK EQUITY ANALYTICS INC. SHALL NOT BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, RELIANCE OR SPECIAL DAMAGES FOR HARM TO BUSINESS, LOST PROFITS, LOST SAVINGS, OR LOST REVENUES, WHETHER OR NOT PATCHELL BROOK EQUITY ANALYTICS INC. HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. PATCHELL BROOK EQUITY ANALYTICS INC. SHALL NOT BE LIABLE FOR ANY DAMAGE THAT ANY USER MAY SUFFER ARISING OUT OF THE USE OF; OR THE INABILITY TO USE, SERVICES OR CONTENT PROVIDED HEREUNDER. THESE LIMITATIONS OF LIABILITY SHALL APPLY REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT OR TORT, AND SHALL SURVIVE FAILURE OF AN EXCLUSIVE REMEDY.<\/strong>
\n © 2017 Patchell Brook Equity Analytics Inc.\n <\/div>\n<\/p><\/div>\n<\/div>\n

<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Print This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all …<\/p>\n

Agios Pharmaceuticals (AGIO:NAS) Fundamental Valuation Report<\/span> Read More »<\/a><\/p>\nRead More<\/i><\/a>","protected":false},"author":288,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"enabled":false},"version":2}},"categories":[3],"tags":[1123,1122,12,1121,1120,1126,1124,1125,10,29,30,1127,8,1129,1128,9,1130,1131,33,6],"class_list":["post-1039","post","type-post","status-publish","format-standard","hentry","category-fundamental-valuation-report","tag-acad","tag-acadia-pharmaceuticals","tag-adjusted-book-value","tag-agio","tag-agios-pharmaceuticals","tag-amicus-therapeutics","tag-array-biopharma","tag-arry","tag-comps","tag-dcf","tag-discounted-cash-flow","tag-fold","tag-fundamental-analysis","tag-icpt","tag-intercept-pharmaceuticals","tag-intrinsic-value","tag-madrigal-pharmaceuticals","tag-mdgl","tag-undervalued","tag-valuation"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":true,"jetpack-related-posts":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9s44y-gL","_links":{"self":[{"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/posts\/1039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/users\/288"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/comments?post=1039"}],"version-history":[{"count":2,"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/posts\/1039\/revisions"}],"predecessor-version":[{"id":1055,"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/posts\/1039\/revisions\/1055"}],"wp:attachment":[{"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/media?parent=1039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/categories?post=1039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stockcalc.com\/blog\/Reports\/wp-json\/wp\/v2\/tags?post=1039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}